3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Plasma Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hematologic Diseases
1
Cholangiocarcinoma
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Interventions
Gemcitabine
82
Cisplatin
52
Oxaliplatin
36
lenvatinib
24
durvalumab
22
Capecitabine
22
Fluorouracil
20
Leucovorin
15
tislelizumab
11
pembrolizumab
10
apatinib
10
Radiotherapy
10
Albumin-Bound Paclitaxel
10
Radiofrequency Ablation
9
Magnetic Resonance Spectroscopy
9
Irinotecan
9
Floxuridine
9
Liver Transplantation
8
Drug Therapy
8
Cholangiopancreatography, Endoscopic Retrograde
8
130-nm albumin-bound paclitaxel
8
Taxes
7
Platinum
7
Photochemotherapy
7
Panitumumab
7
Biopsy
7
1,2-diaminocyclohexaneplatinum II citrate
7
tremelimumab
6
pemigatinib
6
camrelizumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cholangiocarcinoma
×
Association
×
Clear all
NCT01912053
2018-05-11
MispheC
Center Eugene Marquis
Phase 2
Completed
41 enrolled